CD10 is a protein found on the surface of certain cells in the body. In pathology, it is used as an immunohistochemical (IHC) marker — a specialized laboratory stain applied to tissue samples that highlights cells containing this protein. Pathologists use CD10 as part of a panel of markers to identify which cell types are present in a biopsy, classify lymphomas and leukemias, and distinguish between tumors that may look similar under the microscope. Because CD10 is found in several different normal and abnormal cell types, it is always interpreted alongside other markers rather than used on its own.
Why do pathologists test for CD10?
CD10 testing is most commonly used in three clinical contexts:
- Lymphoma and leukemia classification — CD10 is a characteristic marker of germinal center B cells, which give rise to several important lymphoma types. Its presence or absence helps classify lymphomas and determine their subtype, which directly influences treatment. It is also a key marker in B lymphoblastic leukemia.
- Kidney tumor diagnosis — CD10 is strongly expressed in the tubules of the kidney and is characteristically positive in clear cell renal cell carcinoma, helping confirm the kidney as the site of origin when cancer has spread to other parts of the body.
- Gynecologic and other tumors — CD10 is expressed in endometrial stromal cells and helps diagnose endometrial stromal tumors. It is also used to diagnose solid pseudopapillary neoplasm of the pancreas and to assess the stromal tissue around certain breast cancers.
How is CD10 tested?
CD10 is detected using immunohistochemistry. A thin slice of tumor tissue is placed on a glass slide, and an antibody that binds specifically to CD10 is applied. When CD10 is present, the cells undergo a visible color change under the microscope. This test is performed on tissue from a biopsy or surgical specimen — it does not measure CD10 in the blood.
How results are reported
CD10 results are reported as positive or negative, often with a description of the staining pattern and the proportion of cells that stain. The location of the staining within the cell or tissue is important and varies by context:
- Positive — cell membrane staining — the classic pattern in lymphomas and leukemias. In B lymphoblastic leukemia, follicular lymphoma, Burkitt lymphoma, and germinal center-type diffuse large B-cell lymphoma (DLBCL), CD10 positivity on the cell surface is an expected and diagnostically useful finding.
- Positive — canalicular staining in the liver — a specific pattern in which CD10 staining appears in a fine network between hepatocytes (liver cells) rather than in individual cells. This pattern supports a diagnosis of hepatocellular carcinoma rather than a metastatic tumor from another organ.
- Positive — stromal staining — CD10 in the supportive tissue (stroma) around tumor cells rather than in the tumor cells themselves. This pattern is characteristic of endometrial stromal tumors and can also have prognostic significance in some breast cancers.
- Negative — absence of CD10 staining. In the context of lymphoma classification, a negative CD10 result, combined with other markers, helps identify non-germinal center subtypes of DLBCL, which may have different prognoses and treatment approaches.
How does CD10 fit with other markers?
CD10 is almost always interpreted alongside a broader panel of IHC markers. The specific combination depends on the clinical question:
- In B lymphoblastic leukemia, CD10 is evaluated with markers such as CD19, CD79a, and TdT to confirm the diagnosis and determine the stage of B cell development.
- In DLBCL, CD10 is used with BCL6 and MUM1 to classify the lymphoma as a germinal center or non-germinal center subtype, with prognostic and therapeutic implications.
- In follicular lymphoma, CD10 is typically combined with CD20, BCL2, and BCL6 to confirm the germinal center origin of the lymphoma cells.
- In kidney tumors, CD10 is used alongside PAX8, CAIX, and CK7 to help classify the type of renal cell carcinoma and distinguish primary kidney tumors from metastatic disease.
Questions to ask your doctor
- Why was CD10 tested in my biopsy, and was the result positive or negative?
- How does my CD10 result fit with the other markers that were tested?
- Does the CD10 result help confirm my diagnosis or influence my treatment plan?
Related articles on MyPathologyReport.com
We are proud to partner with:
